Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Multiple Myeloma
Study Phase
Phase 3
Study Completion Date
July 2016
NCT00644228Uploaded 08-21-2019
Access via NCI by Request
PDS UID - nci-data-360
A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients With Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant
Files: NCT00644228-D2
Data DictionaryNCT00644228-D2-Data-Dictionary.pdf
DATANCT00644228-D2-Dataset.csv
OTHERREADME.pdf
Files: NCT00644228-D1
Data DictionaryNCT00644228-D1-Data-Dictionary.pdf
DATANCT00644228-D1-Dataset.csv
OTHERREADME.pdf